[Hematological toxicity of ticlopidine? (author's transl)].
Four cases of bone marrow aplasia, with temporary agranulocytosis (one of them fatal) are described in patients treated with Ticlopidine, an anti-aggregating drug prescribed for prevention of thromboembolic disease. These data suggest that a systematic hematological assessment would be required in the first three months after initiation of Ticlopidine therapy.
D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010198:Pancytopenia / Q000139:chemically induced*; D010974:Platelet Aggregation / Q000187:drug effects*; D013876:Thiophenes / Q000009:adverse effects*; D013988:Ticlopidine
D013876:Thiophenes; D013988:Ticlopidine
Toxicité hématologique de la ticlopidine?